Cardiol Rev . The Use of Non-Steroidal Anti-inflammatory Drugs for Coronavirus Disease 2019: Adjunct Therapy

[tetano]

Cardiol Rev


. 2020 Sep 15.
doi: 10.1097/CRD.0000000000000340. Online ahead of print.
The Use of Non-Steroidal Anti-inflammatory Drugs for Coronavirus Disease 2019: Adjunct Therapy


Daniel Zhao ¹ , Sandy Zhang ¹ , Teryn Igawa ¹ , William Frishman ²



Affiliations

• PMID: 32941264
• DOI: 10.1097/CRD.0000000000000340

Abstract

Severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) is the cause of the current coronavirus disease of 2019 (COVID-19) pandemic, a tremendous cause of morbidity and mortality worldwide. Although there are numerous trials underway, there is currently no medication known to cure the infection. Non-steroidal anti-inflammatory drugs (NSAIDs) are inexpensive, widely available medications with antiviral and anti-inflammatory properties, and may have utility as an adjunct therapy to improve outcomes in patients with severe COVID-19 infection. A thorough PubMed literature review on the therapeutic use of NSAID was conducted to provide a comprehensive perspective of the role of NSAIDs in treating COVID-19. NSAIDs may be a useful adjunct therapy for patients with severe COVID-19 infection, but further investigation and clinical trials are necessary to ensure their safety and efficacy.